Drug
Quinidine clinical trials
- studies test it
- 29
- open now
- 1
- in phase 3
- 6
- first study started
- 2007
Keep track of what changes. Save the Quinidine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 5 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 8
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 5
Otsuka Pharmaceutical Development & Commercialization, Inc. (13) · Enanta Pharmaceuticals, Inc (5) · AstraZeneca (2) · Boehringer Ingelheim (2) · Eli Lilly and Company (1) · Bristol-Myers Squibb (1) · University of Florida (1) · James Murrough (1)
Often tested with
Tested in the same studies.
Deudextromethorphan (13) · Itraconazole (4) · Dextromethorphan (3) · Carbamazepine (2) · Fluconazole (2) · Verapamil (2) · Dabigatran (2) · Orforglipron (1)
Studies
Open first, then newest update. How each study uses Quinidine is read from its arms, and is right about nine times in ten.
Testing it · 29
- Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular FibrillationEnrolling by invitationPhase 2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT05593757Written as Quinidine
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaTerminatedPhase 2/3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03896945Written as AVP-786
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06704763Written as Quinidine
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual SchizophreniaCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02477670Written as AVP-786
- Safety, Tolerability and Efficacy of AVP-786 for the Treatment of DisinhibitionTerminatedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02534038Written as AVP-786
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy VolunteersCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02174835Written as AVP-786
- Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult SubejctsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02402595Written as AVP-786
- A Phase 1 Study Comparing AVP-786 With AVP-923CompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02336347Written as AVP-786
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02446132Written as AVP-786
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06493409Written as Quinidine
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With QuinidineCompletedPhase 1AstraZenecaNCT06974565Written as Quinidine
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.CompletedPhase 1Enanta Pharmaceuticals, IncNCT06847464Written as Quinidine
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04464564Written as AVP-786
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04408755Written as AVP-786
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03393520Written as AVP-786
- Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.CompletedPhase 1Enanta Pharmaceuticals, IncNCT05594602Written as Quinidine
- Impact of Nuedexta on Bulbar Physiology and Function in ALSCompletedPhase 1/2University of FloridaNCT03883581Written as dextromethorphan HBr and quinidine sulfate
- Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02442765Written as AVP-786
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive DisorderTerminatedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03420222Written as AVP-786
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy SubjectsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02174822Written as AVP-786
See all 29 studies that test Quinidine →
Given in every arm · 4 — Quinidine is usual care beside what is tested
- A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05444556Written as Quinidine
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.CompletedPhase 1AstraZenecaNCT06979388Written as quinidine
- Empiric Quinidine for Asymptomatic Brugada SyndromeWithdrawnPhase 2/3International Registry of Asymptomatic Brugada SyndromeNCT00789165Written as quinidine
- Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy MalesCompletedPhase 1CelgeneNCT01712828Written as Quinidine
Codes
What other systems call Quinidine · ClinicalTrials.gg INT008144
- MeSH (NLM) D011802QuinidineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ITX08688JLQUINIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 9068Confirmed FDA, Wikidata
- Wikidata Q412496quinidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C793QuinidineOne source FDA
- DrugBank DB00908One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D011802 | Quinidine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ITX08688JL | QUINIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 9068 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412496 | quinidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C793 | Quinidine | One source FDA |
| DrugBank | DB00908 | — | One source Wikidata |
Also registered as quinidine sulfate (UNII J13S2394HE · RxNorm 9069).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.